These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7383465)

  • 1. Prostaglandin E2 vaginal suppositories in pregnancy with an anencephalic fetus.
    Boehm FH; Killam AP; Chambers JF; Davidson KK
    Obstet Gynecol; 1980 Jun; 55(6):758-60. PubMed ID: 7383465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of uterine activity after vaginal administration of prostaglandins.
    Henzl MR; Arvealo TN; Noriega L; Aznar R; Ortega E; Segre E
    Adv Biosci; 1973; 9():767-72. PubMed ID: 4805889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of vaginal prostaglandin E2 suppositories in the management of third-trimester fetal demise.
    Kent DR; Goldstein AI; Linzey EM
    J Reprod Med; 1984 Feb; 29(2):101-2. PubMed ID: 6584630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of intrauterine fetal demise and missed abortion using prostaglandin E2 vaginal suppositories.
    Southern EM; Gutknecht GD
    Obstet Gynecol; 1976 May; 47(5):602-6. PubMed ID: 1264407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of extrauterine fetal death with failure of prostaglandin E2 suppositories.
    Orr JW; Huddleston JF; Goldenberg RL; Knox GE; Davis RO
    Obstet Gynecol; 1979 Mar; 53(3 Suppl):56S-58S. PubMed ID: 424129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal prostaglandin E2 for interruption of pregnancy and management of intrauterine death.
    Thiery M; Amy JJ; Decoster JM
    Z Geburtshilfe Perinatol; 1979 Jun; 183(3):218-22. PubMed ID: 483950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of prostaglandin E2 vaginal suppositories in intrauterine fetal death and missed abortion.
    Bailey CD; Newman C; Ellinas SP; Anderson GG
    Obstet Gynecol; 1975 Jan; 45(1):110-3. PubMed ID: 1110809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midtrimester pregnancy termination for fetal malformations. Use of intravaginal prostaglandin E2.
    Hagar DL; Valley MT; Rayburn WF; Carey JC
    J Reprod Med; 1997 Aug; 42(8):497-500. PubMed ID: 9284011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare obstetric contraindication to the use of vaginal prostaglandins for fetal demise.
    Waszak SJ
    J Reprod Med; 1979 Apr; 22(4):204-6. PubMed ID: 458763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midtrimester pregnancy termination with prostaglandin E2 vaginal suppositories.
    Hochman M; Laufe LE
    J Reprod Med; 1976 May; 16(5):263-8. PubMed ID: 933105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between intraamniotic PGF2 alpha and vaginal PGE2 for second-trimester abortion.
    Lebed JP; Rubin A; Millman AE
    Obstet Gynecol; 1980 Jul; 56(1):90-6. PubMed ID: 7383493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between vaginal prostaglandin E2 suppositories and intrauterine extra-amniotic prostaglandins in the management of fetal death in utero.
    Scher J; Jeng DY; Moshirpur J; Kerenyi TD
    Am J Obstet Gynecol; 1980 Aug; 137(7):769-72. PubMed ID: 7405968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uterine rupture associated with the use of vaginal prostaglandin E2 suppositories.
    Keller F; Joyce TH
    Can Anaesth Soc J; 1984 Jan; 31(1):80-2. PubMed ID: 6581851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrauterine (extraamniotic) prostaglandins in the management of unsuccessful pregnancy.
    Calder AA; Mackenzie IZ; Embrey MP
    J Reprod Med; 1976 May; 16(5):271-5. PubMed ID: 933106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E2 vaginal suppositories for therapeutic abortion.
    Newman C; Bailey CD; Ellinas SP; Anderson GG
    Adv Plan Parent; 1975; 10(1):34-8. PubMed ID: 1164986
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of postpartum uterine atony with prostaglandin E2 vaginal suppositories.
    Hertz RH; Sokol RJ; Dierker LJ
    Obstet Gynecol; 1980 Jul; 56(1):129-30. PubMed ID: 6966776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early midtrimester pregnancy termination. A comparison of dilatation and evacuation and intravaginal prostaglandin E2.
    Robins J; Surrago EJ
    J Reprod Med; 1982 Jul; 27(7):415-9. PubMed ID: 6956734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentrated oxytocin plus low-dose prostaglandin E2 compared with prostaglandin E2 vaginal suppositories for second-trimester pregnancy termination.
    Owen J; Hauth JC
    Obstet Gynecol; 1996 Jul; 88(1):110-3. PubMed ID: 8684741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin E2 vaginal suppositories in the treatment of intractable late-onset postpartum hemorrhage. A case report.
    Goldstein AI; Kent DR; David A
    J Reprod Med; 1983 Jun; 28(6):425-6. PubMed ID: 6604156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin vaginal suppositories: a simple and safe approach to the induction of labor.
    Shepherd JH; Bennett MJ; Laurence D; Moore F; Sims CD
    Obstet Gynecol; 1981 Nov; 58(5):596-600. PubMed ID: 6946350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.